A detailed history of Vanguard Group Inc transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 8,265,459 shares of TSHA stock, worth $16.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
8,265,459
Previous 7,167,337 15.32%
Holding current value
$16.8 Million
Previous $16.1 Million 3.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.01 - $2.46 $2.21 Million - $2.7 Million
1,098,122 Added 15.32%
8,265,459 $16.6 Million
Q2 2024

Aug 13, 2024

BUY
$2.04 - $4.17 $2.55 Million - $5.21 Million
1,249,923 Added 21.12%
7,167,337 $16.1 Million
Q1 2024

May 10, 2024

SELL
$1.43 - $3.25 $397,758 - $903,997
-278,153 Reduced 4.49%
5,917,414 $17 Million
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $1.15 Million - $2.5 Million
867,703 Added 16.29%
6,195,567 $11 Million
Q3 2023

Nov 14, 2023

BUY
$0.63 - $3.66 $2.36 Million - $13.7 Million
3,738,616 Added 235.24%
5,327,864 $16.8 Million
Q2 2023

Aug 14, 2023

BUY
$0.59 - $0.87 $3,427 - $5,054
5,810 Added 0.37%
1,589,248 $1.05 Million
Q1 2023

May 15, 2023

BUY
$0.65 - $2.3 $18,051 - $63,875
27,772 Added 1.79%
1,583,438 $1.27 Million
Q4 2022

Feb 10, 2023

BUY
$1.39 - $2.98 $673,960 - $1.44 Million
484,864 Added 45.28%
1,555,666 $3.52 Million
Q2 2022

Aug 12, 2022

BUY
$2.47 - $6.77 $144,835 - $396,979
58,638 Added 5.79%
1,070,802 $3.98 Million
Q1 2022

May 13, 2022

BUY
$5.22 - $11.86 $670,858 - $1.52 Million
128,517 Added 14.54%
1,012,164 $6.6 Million
Q4 2021

Feb 14, 2022

BUY
$11.43 - $19.2 $890,728 - $1.5 Million
77,929 Added 9.67%
883,647 $10.3 Million
Q3 2021

Nov 12, 2021

BUY
$15.82 - $21.57 $2.8 Million - $3.82 Million
177,074 Added 28.17%
805,718 $15 Million
Q2 2021

Aug 13, 2021

BUY
$19.29 - $26.38 $12.1 Million - $16.6 Million
628,644 New
628,644 $13.3 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $98.2M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.